Recombinant Human BCAM Protein, His-tagged

• Cat.No.: EPO-200H
• Product Overview: Recombinant Human EPO protein(NP_000790.2) (Met1-Arg193) was expressed in HEK293 with the Fc region of human IgG1 at the C-terminus.

Specification

• Species: Human
• Source: HEK293
• Tag: Fc
• Protein Length: 1-193 aa
• Form: Lyophilized from sterile PBS, pH 7.4.
• Molecular Mass: The recombinant human EPO consists 404 amino acids and predicts a molecular mass of 45.1 kDa.
• Endotoxin: < 1 EU/µg as determined by LAL test.
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Store it under sterile conditions at -20°C to -80°C upon receiving. Recommend to aliquot the protein into smaller quantities for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Gene Information

• Gene Name: EPO erythropoietin [ Homo sapiens ]
• Official Symbol: EPO
• Synonyms: EPO; erythropoietin; EP; epoetin; MVCD2; MGC138142
• Gene ID: 2056
• mRNA Refseq: NM_000799
• Protein Refseq: NP_000790
• MIM: 133170
• UniProt ID: P01588

Citation

Dual Delivery of EPO and BMP2 from a Novel Modular Poly-?-Caprolactone Construct to Increase the Bone Formation in Prefabricated Bone Flaps

Journal: Tissue Engineering. Part C, Methods    PubMed ID: 25809081    Data: 2015/9/1

Authors: Janki Jayesh Patel, Jane E. Modes, Scott J. Hollister

Article Snippet:BMP2, bone morphogenetic protein-2; EPO, erythropoietin.BMP2, bone morphogenetic protein-2; EPO, erythropoietin.. EPO binding to PCL scaffolds One hundred micrograms of EPO (Creative BioMart) was reconstituted in 1 mL sterile Dulbecco's phosphate-buffered saline (DPBS) to result in 12,000 IU/mL (0.1 mg/mL).. The stock solution was further diluted to the desired concentrations in DPBS.The stock solution was further diluted to the desired concentrations in DPBS.

Modular scaffold assembly. BMP2 was adsorbed onto the inner scaffold module and EPO was adsorbed onto the outer scaffold module. The two scaffolds were then assembled. BMP2, bone morphogenetic protein-2; EPO, erythropoietin.

Protein release profiles. (A) BMP2 cumulative release profile. After 7 days, 0.0311±0.0053 μg BMP2 was released into phosphate-buffered saline at 37°C. (B) BMP2 release. A small burst release occurred in the first 2 days, followed by sustained release. (C) EPO cumulative release profile. After 7 days, 119.2±29.4 IU of the 139.6±28.6 IU that was bound was released. (D) EPO released over 7 days with a small burst release in the first 2 days. (n=3/group).

Adsorbed EPO bioactivity. HUVECs seeded on the PCL disc exposed to EPO showed increased levels of proliferation. n=4; *p<0.05. HUVEC, human umbilical vein endothelial cells; PCL, poly-?-caprolactone.